anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This is an open-label (identity of study drug will be known to participant and study staff), multicenter (when more than one hospital or medical school team work on a medical research study), Phase 1b study. The purpose of this study is to see if duvortuxizumab in combination with ibrutinib is safe and useful for treating participants with B-cell malignancies. This study will be conducted in 2 parts: Part 1: Dose Optimization and Part 2: Dose Expansion. Part 1 will determine what dose of duvortuxizumab can be given safely with the standard dose of ibrutinib to participants with previously treated B-cell malignancies. Part 2 will look at how previously treated DLBCL, FL, MCL, and CLL participants respond to a safe dose of duvortuxizumab in combination with ibrutinib. Part 2 will also test whether the dose from Part 1 is an effective cancer therapy. The study consists of a Screening Phase, an ibrutinib Run-In Phase (Part 2 only), a combination (duvortuxizumab plus ibrutinib) Treatment Phase (Day 1, Cycle 1 and continues until the completion of the End-of-Treatment Visit), End-of-Treatment Visit (30 days (+7 days) after the last dose of study drug), and Post-treatment Follow-up Phase. The end of the study will be defined as 12 months after the last participant has received the first dose of study treatment. Participants' safety will be monitored throughout the study.
PURPOSE:To prepare a composition for oral cavity application, having improved stability, by compounding hydroxyethyl cellulose added with a specific amount of ethylene oxide. CONSTITUTION:An oral cavity composition containing 0.5-4wt% of hydroxyethyl cellulose added with 1.8-2.8mol., pref. 2.0-2.5mol of ethylene oxide. The addition of the above compound prevents the salting-out of hydroxyethyl cellulose even in the presence of a large amount of electrolyte, and suppresses the variation  of the viscosity of the system. Consequently, there is no trouble of powder coagulation when used in a powder-containing system, e.g. tooth paste composition, and  the system thus obtained has excellent surface appearance and is resistant to the  solid-liquid separation even by storing under hot conditions for a long period.
The invention provides an injection prepared from a novel composition which contains three medicines such as fructose diphosphate and the like, wherein the injection consists of the following components according to effective doses: 10-50g of the fructose diphosphate, 0.01-0.05g of isosorbide dinitrate and 100-1000ml of sodium hydrogen sulfite. The invention also provides preparation steps and a preparation method. The pharmaceutical composition is applicable to shock, coronary heart disease, angina, acute myocardial infarction, myocardial ischemia, cardiac failure and surrounding lesions. By adding the isosorbide dinitrate, myocardial oxygen consumption is reduced, oxygen supply is enhanced and the angina is relieved. In cooperation with and by expanding the application of the fructose diphosphate to clinical treatment, the medicine is safer and is more stable, and the medicine is capable of relieving irritant pain on a human body and enhancing a curative effect on treating circulation system related diseases. The preparation method comprises the following steps: sequentially stirring and dissolving the fructose diphosphate, the sodium hydrogen sulfite and the isosorbide dinitrate by virtue of injection water, decoloring with the addition of activated carbon, filtering and removing carbon; and filtering, sterilizing, filling and sterilizing.
PROBLEM TO BE SOLVED: To keep anatoxin in a solution and utilize anatoxin pertussis dissolved in a specific buffer directly for the production of vaccine by carrying out the detoxification of pertussis toxin in the buffer. SOLUTION: Pertussis toxin is detoxificated in a carbonate buffer of pH 8.3-11.6 with a common detoxification agent (e.g. formal or glutaraldehyde). The buffer can be produced e.g. by dissolving a mixture of sodium or potassium bicarbonate and sodium or potassium carbonate in water. The molar concentration of the buffer is preferably 0.025-0.5 M. The buffer preferably further contains a surfactant such as sorbitan polyoxyethylene (20) monooleate at a concentration of <=5.0 wt.%. The pertussis toxin is preferably produced e.g. by purifying the supernatant of the cultured medium of bacteria of the genus Bordetella by affinity chromatography.
Introduction: Bardet-Biedl syndrome (BBS) is a rare autosomal recessive disorder with clinical features of retinal dystrophy, obesity, postaxial polydactyly, renal anomalies, learning disabilities, hypogonadism, and genitourinary abnormalities. Nevertheless, previous studies on the phenotypic traits of BBS heterozygous carriers have generated inconclusive results. The aim of our study was to investigate the impact of BBS heterozygosity on carriers when compared to non-carriers within the Taiwanese population. Materials and Methods: This study follows a hospital-based case-control design. We employed the Taiwan Biobank version 2 (TWBv2) array to identify three specific loci associated with BBS (rs773862084, rs567573386, and rs199910690). In total, 716 patients were included in the case group, and they were compared to a control group of 2,864 patients who lacked BBS alleles. The control group was selected through gender and age matching at a ratio of 1:4. The association between BBS-related loci and comorbidity was assessed using logistic regression models. Results: We found that BBS heterozygous carriers exhibited a significant association with elevated BMI levels, especially the variant rs199910690 in MKS1 (p=0.0037). The prevalence of comorbidities in the carriers' group was not higher than that in the non-carriers' group. Besides, the average values of the biochemistry data showed no significant differences, except for creatinine level. Furthermore, we conducted a BMI-based analysis to identify specific risk factors for chronic kidney disease (CKD). Our findings revealed that individuals carrying the CA/AA genotype of the BBS2 rs773862084 variant or the CT/TT genotype of the MKS1 rs199910690 variant showed a reduced risk of developing CKD, irrespective of their BMI levels. When stratified by BMI level, obese males with the MKS1 rs199910690 variant and obese females with the BBS2 rs773862084 variant exhibited a negative association with CKD development. Conclusion: We found that aside from the association with overweight and obesity, heterozygous BBS mutations did not appear to increase the predisposition of individuals to comorbidities and metabolic diseases. To gain a more comprehensive understanding of the genetic susceptibility associated with Bardet-Biedl Syndrome (BBS), further research is warranted.
This study will use telemedicine to facilitate an innovative use of "rolling refresher" training (RRT), a technique used in medical education to provide hands-on interactive training at regular intervals with the goal of improving psychomotor skills required for high stakes procedures such as cardiopulmonary resuscitation. This study seeks to interrogate our hypothesis that providing instruction on CSS use to caretakers via telemedicine every 3 months during the first year of an infant's life is feasible and acceptable to caregivers.
Patients receive perflutren or sulfur hexafluoride lipid microspheres and undergo CEUS at baseline, 2 and 4 weeks, and 3 and 6 months. Patients also undergo PET/CT after standard of care 90Y radioembolization at baseline.
?927PP.APP(FF)                                             PATENT                Lawter & Sherman Case 1 Combined with Hussain Case 1 CARRIER COMPOSITION AND METHOD                    Abstract of the Invention A composition and method of making it.  The composition includes a carrier and particles adhered to the carrier.  The particles include oil and water soluble matrix material.  The encapsulation material is water soluble.  The oil is encapsulated by the encapsulation material.  The carrier is substantially insoluble in the water.
The older adults with mental health issues group is crucial for examining the impact of Anxiety and/or Depression on cognitive aging. Participants aged over 60 diagnosed with these conditions are included while still demonstrating healthy aging from a cognitive standpoint. This ensures that any observed cognitive differences can be attributed to mental health conditions rather than age-related decline alone.
Food restriction can have profound effects on various aspects of behavior, physiology, and morphology. Such effects might be amplified in animals that are highly active, given that physical activity can represent a substantial fraction of the total daily energy budget. More specifically, some effects of food restriction could be associated with intrinsic, genetically based differences in the propensity or ability to perform physical activity. To address this possibility, we studied the effects of food restriction in four replicate lines of High Runner (HR) mice that have been selectively bred for high levels of voluntary wheel running. We hypothesized that HR mice would respond differently than mice from four non-selected Control (C) lines. Healthy adult females from generation 65 were housed individually with wheels and provided access to food and water ad libitum for experimental days 1-19 (Phase 1), which allowed mice to attain a plateau in daily running distances. Ad libitum food intake of each mouse was measured on days 20-22 (Phase 2). After this, each mouse experienced a 20 % food restriction for 7 days (days 24-30; Phase 3), and then a 40 % food restriction for 7 additional days (days 31-37; Phase 4). Mice were weighed on experimental days 1, 8, 9, 15, 20, and 23-37 and wheel-running activity was recorded continuously, in 1-minute bins, during the entire experiment. Repeated-measures ANOVA of daily wheel-running distance during Phases 2-4 indicated that HR mice always ran much more than C, with values being 3.29-fold higher during the ad libitum feeding trial, 3.58-fold higher with -20 % food, and 3.06-fold higher with -40 % food. Seven days of food restriction at -20 % did not significantly reduce wheel-running distance of either HR (-5.8 %, P = 0.0773) or C mice (-13.3 %, P = 0.2122). With 40 % restriction, HR mice showed a further decrease in daily wheel-running distance (P = 0.0797 vs. values at 20 % restriction), whereas C mice did not (P = 0.4068 vs. values at 20 % restriction) and recovered to levels similar to those on ad libitum food (P = 0.3634). For HR mice, daily running distances averaged 11.4 % lower at -40 % food versus baseline values (P = 0.0086), whereas for C mice no statistical difference existed (-4.8 %, P = 0.7004). Repeated-measures ANOVA of body mass during Phases 2-4 indicated a highly significant effect of food restriction (P = 0.0001), but no significant effect of linetype (P = 0.1764) and no interaction (P = 0.8524). Both HR and C mice had a significant reduction in body mass only when food rations were reduced by 40 % relative to ad libitum feeding, and even then the reductions averaged only -0.60 g for HR mice (-2.6 %) and -0.49 g (-2.0 %) for C mice. Overall, our results indicate a surprising insensitivity of body mass to food restriction in both high-activity (HR) and ordinary (C) mice, and also insensitivity of wheel running in the C lines of mice, thus calling for studies of compensatory mechanisms that allow this insensitivity.
PROBLEM TO BE SOLVED: To obtain a hyaluronidase inhibitor having excellent hyaluronidase- inhibitory activity, preferably a hyaluronidase inhibitor prepared in the cosmetic form. SOLUTION: This inhibitor contains rosmarinic acid obtained by extraction of perilla plants in an amount of 0.001-5wt.%, preferably 0.005-1wt.%. In addition, usual excipient, auxiliary agents and additives are appropriately formulated to give face-washing cream, cosmetic lotion, emulsion and other cosmetics. The rosmarinic acid is obtained by extracting perilla plants such as beefsteak plant, green perilla, perilla frutescens Britton var. crispa Decaisnef. crispa Makino, rosemary or the like or by chemical synthesis. Extraction is convenient and water or ethanol is used as a solvent to effect the extraction at room temperature to 100 deg.C. This cosmetic prevents skin roughening and fine wrinkles and can keep moistening feeling.
Formulations are described for the treatment by enzymatic debridement of wounds and ulcers. The formulations have a clear, transparent composition that allows for easy visualization of the wound, and are non-staining for easy clean up. These formulations can also exhibit increased enzymatic debridement activity, improved post-treatment lubricity and coating occlusivity, and stability. The formulations, optionally containing non-animal source biologics, may be in the form of lotions, aerosols to provide a spray, or a foam. A non-reactive substrate may be used as a composition carrier. A non-aqueous lotion formulation having improved enzymatic activity is provided. The non-aqueous lotion viscosity is adjusted to achieve high enzymatic activity while maintaining the application benefits of high viscosity non-aqueous lotions. The lotion formulation may be delivered in a patch.
Patients will be treated with 150-375 milligrams of Omalizumab (Xolair), based on their baseline weight and serum Immunoglobulin E levels. Omalizumab will be administered subcutaneously on Day 1, and on Week 2, 4, 6, 8, 10, 12 and 14 treatment.
BACKGROUND AND AIMS: Active Surveillance (AS) is a favored strategy for the management of indolent prostate cancers (PCs). Overweight and obese men harbor an increased risk of cancer progression during AS. We aim to prospectively evaluate the feasibility and outcomes of a ketogenic diet (KD) weight-loss intervention in overweight men with PC.
MATERIALS AND METHODS: Men with PC and a BMI > 25 kg/m2 undergoing AS were placed on an 8-week ad libitum KD program before a scheduled surveillance biopsy to assess the impact on clinical grade group (CGG). Blood ketone levels were tracked to ensure compliance. BMI, PSA, and inflammatory marker data (TNF-α, TNFR1, TNFR2, sICAM-1, sVCAM-1, IL-6, IL1-RA, CRP, and SAA) were collected before and after the KD intervention. A Shapiro-Wilk test was performed to assess the normality of all continuous study variables. Paired t-tests and Wilcoxon rank sum tests were utilized to compare normally and non-normally distributed study outcomes, respectively.
RESULTS: Ten AS patients aged 62.1 (±5.4) years were enrolled with an average BMI of 31.7 kg/m2 (±11.8). Post-KD intervention mean blood ketone levels were 0.32 (±0.12) mmol/L with a mean BMI reduction of 7.4% (p < 0.0003). There were no meaningful changes in PSA or inflammatory biomarkers (p > 0.05). Nine patients completed re-biopsy following a KD with four patients showing no evidence of cancer; one downgraded to a lower CGG; two had unchanged CGG scores; and two had higher CGG scores compared to baseline.
CONCLUSIONS: Short-term KD interventions for BMI reduction are feasible in men undergoing AS for PC and may result in favorable pathological effects without inflammatory marker changes. Larger studies with longer follow-up are needed to explore whether KD-induced weight loss can improve clinical outcomes with AS in PC.
Motor imagery is defined as the mental process of simulating a certain action without any movement. In one study, researchers showed that motor imagery training activates the sensorimotor system and that brain plasticity resulting from actual movement execution also occurs as a result of motor imagery. When the literature is examined, it has been reported in studies that muscle strength may increase as a result of imagery training. However, there are also studies reporting that imagery training is effective on performance in basketball players.

Dynamic motor imagery, on the other hand, is a type of motor imagery in which the athletes adopt a harmonious body position and embody the spatial and/or temporal invariants of the movement without fully realizing it. According to a study, dynamic imagery training has a positive effect on free throw performance in basketball players. To facilitate sensorimotor relearning, which is a new training model, motor imagery training is an approach that approaches athletes with a holistic perspective, combining both physical exercises and dynamic motor imagery training. In a study, it was reported that training is more fun than just physical exercises . When the literature is examined; no study has been found examining the effects of motor imagery training on performance and heart rate changes in order to facilitate sensorimotor relearning in adolescent basketball players.
This randomized controlled trial aims to assess effects of videoconferencing acceptance and commitment therapy (ACT) on mental health outcomes in individuals living with spinal cord injuries (SCI). A total of 40 individuals living with SCI sustained within 5 years and experiencing depressive symptoms will be recruited and randomly assigned to either the ACT group or the wait-list control group. The ACT group will receive 8 weekly individual ACT sessions guided by a coach through videoconferencing. The wait-list group will receive ACT sessions after the study period ends. We will provide psychoeducation materials related to SCI as supplemental resources to both groups. Mental health outcomes using self-reported questionnaires will be collected at pretest, posttest, and 2-month follow-up. Exploratory hypotheses are that the group undergoing the ACT intervention supplemented with psychoeducation will show improvements in depression (primary outcome), secondary mental health outcomes (e.g., anxiety, stress, and grief), and ACT processes (e.g., psychological flexibility) at posttest and 2-month follow-up, compared to the wait-list control group provided with psychoeducation materials alone. Interviews will be conducted at posttest to explore the participants' experiences in ACT.
Endotracheal intubation with video fiberscope: The group in which DrHalil Cebeci applied endotracheal intubation using a video fiberscope( Karl Storz GmbH \&Co. KG, Tuttlingen, Germany) consisted of 15 patients. Endotracheal intubation was performed by two practitioners using two different devices. Intubation times, number of attempts, failed attempts, postoperative complications and hemodynamic responses were recorded.
INTRODUCTION: Due to the increasing number of cochlear implant (CI) recipients, growing indications, and the aging population, the reimplantation of CI recipients has become a focus of attention. The aim of this study is to examine the causes, timing, and postoperative speech understanding in a large cohort over the past 30 years.
METHODS: A retrospective data analysis was conducted on over 4000 CI recipients and 214 reimplanted children and adults from 1993 to 2020. This involved collecting and comparing data on causes, manufacturer information, and demographic data. In addition, a comparison of speech understanding in Freiburg monosyllables and numbers before and after reimplantation was carried out.
RESULTS: Children did not exhibit elevated rates of reimplantation. The overall reimplantation rate in the entire cohort was 5%. The CI overall survival rate after 10 years in the entire cohort was 95.2%. Device failure was the most common reason for reimplantation, with 48% occurring within the first 5 years after implantation. The second most common reason was medical complications, with the risk of reimplantation decreasing as more time passed since the initial implantation. There were no significant differences in Freiburg numbers and monosyllable comprehension before and after reimplantation, both in the overall cohort and in the subcohorts based on indications. Even a technical upgrade did not result in a significant improvement in speech understanding.
DISCUSSION: There was no significant difference in the frequency of reimplantation based on patient age, especially when comparing children and adults. Device failure is by far the most common indication for reimplantation, with no significant difference in implant survival between manufacturers. Patients most often choose the same manufacturer for reimplantation. The likelihood of reimplantation decreases with increasing time since the initial implantation. The indication for reimplantation should be carefully considered, as on average, no improved speech understanding is achieved, regardless of the cause, even with a technical upgrade.
The goal of this clinical trial is to evaluate the efficacy and safety of actinomycin-D with or without toripalimab as fist-line treatment in patients with gestational trophoblastic neoplasia with FIGO score 5-6.

Eligible Participants will be randomized into two groups. Those in experimental group will receive toripalimab (200mg q2w intravenous) plus actinomycin-D (1.25mg/m2，2mg max dose, intravenous). While those in control group will receive actinomycin-D (1.25mg/m2，2mg max dose, intravenous) alone. After normalization of serum β-human chorionic gonadotropin (β-hCG) levels, patients will receive 3 cycles of consolidation treatment. Treatment will be continued until completion of treatment, disease progression, unacceptable toxicity, or withdrawal of consent. The primary endpoint is complete remission rate (the proportion of patients achieving complete remission). Secondary endpoints include objective response rate (the proportion of patients achieving complete remission and partial remission), progression-free survival (time from the treatment initiation to disease progression or death, whichever comes first), disease control rate, duration of response, overall survival (time from the treatment initiation to the date of death or last follow-up), duration of response (time from the first evidence of response to disease progression or death, whichever comes first) safety, biomarker, ovarian function and quality of life.
The present invention relates to the technical field of medicine, which relates to a Barbe preparation as a novel preparation of cetirizine hydrochloride as antihistamine medicine. Cetirizine hydrochloride is clinically common medicine, and the existing preparations of cetirizine hydrochloride comprise oral-administration preparations such as tablets, capsules, solution preparations, etc. Because cetirizine hydrochloride performs the centrum inhibiting function, patients taking the medicine have adverse reaction such as somnolence, vertigo, headache, etc. Cetirizine hydrochloride is used as main medicine of the present invention, and different auxiliary materials are added to the main medicine for manufacturing the Barbe preparation. The Barbe preparation is fed by a skin penetrating method, so the stimulation to the gastrointestinal tract caused by oral administration can be avoided, the systemic blood concentration can be reduced, the centrum inhibiting function can be reduced, and the medicine concentration on local affected parts can be improved. Moreover, the Barbe preparation has the advantages that administration frequency can be reduced, the Barbe preparation can be used conveniently, the medication compliance of patients can be improved, etc. The present invention provides a novel administration preparation for the clinical application of cetirizine.